NEWS | alsv

Companies in the News

17 hours ago

Indigo Ag and Truterra launch strategic collaboration to accelerate adoption of agriculture sustainability solutions

BOSTON, Nov. 18, 2024 /PRNewswire/ -- Indigo Ag and Truterra today announced a strategic collaboration aimed at simplifying, expanding...

Oct 25

Tessera Therapeutics Presents New Preclinical Data in In Vivo AATD and SCD Programs at the 31st Annual Congress of the European Society of Gene and Cell Therapy

A single intravenous administration of Gene Writer™ resulted in an estimated 79% hepatocyte genomic editing with an average of 84% of...

Oct 9

Startup led by John Maraganore raises $135M to build ‘future of RNAi’

Since stepping down as CEO of Alnylam Pharmaceuticals three years ago, John Maraganore has lent his talents widely, joining the boards of...

Sep 25

Novartis inks $1B-plus biobucks deal with Flagship's Generate

Novartis has inked a deal potentially worth more than $1 billion with Flagship-founded Generate:Biomedicines to develop protein...

Jun 3

Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual

Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS1-positive NSCLC who were ROS1 TKI-naïve and 52% of those who...

May 30

Incyte Completes Acquisition of Escient Pharmaceuticals

Acquisition strengthens Incyte’s Inflammation and Autoimmunity (IAI) pipeline and reinforces commitment to bring innovative solutions to...

Apr 23

Incyte, fresh off gaining MorphoSys drug, buys Escient for $750M

Incyte is dolloping another deal onto its 2024 partnership plate, buying San Diego-based Escient Pharmaceuticals for $750 million. The...

Mar 25

Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction

Acquisition transforms Nuvation Bio into late-stage global oncology company with potential to become a commercial organization by the end...

Feb 6

Encoded Therapeutics Announces US IND Clearance and Australian CTA Approval for Dravet Syndrome Gene Therapy Candidate ETX101

Initial studies will focus on infants and young children; company plans to begin clinical trials in the United States and Australia in...

2 3 4 5

A L T I T U D E

Life Science Ventures

Companies in the News